• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Atara Biotherapeutics Inc.

    3/18/24 4:13:07 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ATRA alert in real time by email
    SC 13G 1 tm249099d1_sc13g.htm SC 13G

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G*

    (Rule 13d-102)

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT

    TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED

    PURSUANT TO § 240.13d-2

    (Amendment No. __)*

     

    Atara Biotherapeutics, Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.0001 per share (the “Shares”)

    (Title of Class of Securities)
     

    046513107

    (CUSIP Number)
     

    March 8, 2024

    (Date of Event Which Requires Filing of the Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    ¨ Rule 13d-1(b)
    x Rule 13d-1(c)
    ¨ Rule 13d-1(d)

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No. 046513107 13G Page 2 of 13 Pages

     

    1.

    NAME OF REPORTING PERSONS

     

    Citadel Advisors LLC

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)     ¨

    (b)     ¨

    3. SEC USE ONLY
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    6,512,063 Shares

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    See Row 6 above

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    See Row 6 above

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    o

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    6.4%1

    12.

    TYPE OF REPORTING PERSON

     

    IA; OO; HC

     

     

    1 The percentages reported in this Schedule 13G are based upon 101,922,250 Shares outstanding as of October 27, 2023 (according to the issuer’s Form 10-Q as filed with the Securities and Exchange Commission on November 1, 2023). Except as described in the preceding sentence, all Shares for the holdings of the reporting persons reported in this Schedule 13G are as of the opening of the market on March 18, 2024.

     

     

     

     

                     CUSIP No. 046513107 13G Page 3 of 13 Pages

     

    1.

    NAME OF REPORTING PERSONS

     

    Citadel Advisors Holdings LP

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)     o

    (b)     o

    3. SEC USE ONLY
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    6,512,063 Shares

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    See Row 6 above

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    See Row 6 above

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    o

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    6.4%

    12.

    TYPE OF REPORTING PERSON

     

    PN; HC

           

     

     

     

    CUSIP No. 046513107 13G Page 4 of 13 Pages

     

    1.

    NAME OF REPORTING PERSONS

     

    Citadel GP LLC

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)     o

    (b)     o

    3. SEC USE ONLY
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    6,512,063 Shares

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    See Row 6 above

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    See Row 6 above

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    o

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    6.4%

    12.

    TYPE OF REPORTING PERSON

     

    OO; HC

           

     

     

     

    CUSIP No. 046513107 13G Page 5 of 13 Pages

     

    1.

    NAME OF REPORTING PERSONS

     

    Citadel Securities LLC

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)     o

    (b)     o

    3. SEC USE ONLY
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    21,056 Shares

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    See Row 6 above

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    See Row 6 above

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    o

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.0%

    12.

    TYPE OF REPORTING PERSON

     

    BD; OO

           

     

     

     

    CUSIP No. 046513107 13G Page 6 of 13 Pages

     

    1.

    NAME OF REPORTING PERSONS

     

    Citadel Securities Group LP

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)     o

    (b)     o

    3. SEC USE ONLY
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    21,056 Shares

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    See Row 6 above

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    See Row 6 above

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    o

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.0%

    12.

    TYPE OF REPORTING PERSON

     

    PN; HC

           

     

     

     

    CUSIP No. 046513107 13G Page 7 of 13 Pages

     

    1.

    NAME OF REPORTING PERSONS

     

    Citadel Securities GP LLC

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)     o

    (b)     o

    3. SEC USE ONLY
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    21,056 Shares

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    See Row 6 above

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    See Row 6 above

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    o

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0.0%

    12.

    TYPE OF REPORTING PERSON

     

    OO; HC

           

     

     

     

    CUSIP No. 046513107 13G Page 8 of 13 Pages

     

    1.

    NAME OF REPORTING PERSONS

     

    Kenneth Griffin

    2.

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)     o

    (b)     o

    3. SEC USE ONLY
    4.

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    U.S. Citizen

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON
    WITH
    5.

    SOLE VOTING POWER

     

    0

    6.

    SHARED VOTING POWER

     

    6,533,119 Shares

    7.

    SOLE DISPOSITIVE POWER

     

    0

    8.

    SHARED DISPOSITIVE POWER

     

    See Row 6 above

    9.

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    See Row 6 above

    10.

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

    o

    11.

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    6.4%

    12.

    TYPE OF REPORTING PERSON

     

    IN; HC

           

     

     

     

    CUSIP No. 046513107 13G Page 9 of 13 Pages

     

    Item 1(a). Name of Issuer:
       
     

    Atara Biotherapeutics, Inc.

       
    Item 1(b). Address of Issuer’s Principal Executive Offices:
       
     

    2380 Conejo Spectrum Street, Suite 200, Thousand Oaks, California 91320

       
    Item 2(a). Name of Person Filing:
       
      This Schedule 13G is being jointly filed by Citadel Advisors LLC (“Citadel Advisors”), Citadel Advisors Holdings LP (“CAH”), Citadel GP LLC (“CGP”), Citadel Securities LLC (“Citadel Securities”), Citadel Securities Group LP (“CALC4”), Citadel Securities GP LLC (“CSGP”) and Mr. Kenneth Griffin (collectively with Citadel Advisors, CAH, CGP, Citadel Securities, CALC4 and CSGP, the “Reporting Persons”) with respect to the Shares of the above-named issuer owned by Citadel Multi-Strategy Equities Master Fund Ltd., a Cayman Islands company (“CM”), and Citadel Securities.  Such owned Shares may include other instruments exercisable for or convertible into Shares.
       
      Citadel Advisors is the portfolio manager for CM. CAH is the sole member of Citadel Advisors. CGP is the general partner of CAH. CALC4 is the non-member manager of Citadel Securities. CSGP is the general partner of CALC4. Mr. Griffin is the President and Chief Executive Officer of CGP, and owns a controlling interest in CGP and CSGP.
       
      The filing of this statement shall not be construed as an admission that any of the Reporting Persons is the beneficial owner of any securities covered by the statement other than the securities actually owned by such person (if any).
       
    Item 2(b). Address or Principal Business Office or, if none, Residence:
       
      The address of each of the Reporting Persons is Southeast Financial Center, 200 S. Biscayne Blvd., Suite 3300, Miami, Florida 33131.
       
    Item 2(c). Citizenship:
       
      Each of Citadel Advisors, CGP, Citadel Securities and CSGP is organized as a limited liability company under the laws of the State of Delaware. Each of CALC4 and CAH is organized as a limited partnership under the laws of the State of Delaware. Mr. Griffin is a U.S. citizen.
       
    Item 2(d). Title of Class of Securities:
       
     

    Common Stock, par value $0.0001 per share

       
    Item 2(e). CUSIP Number:
       
     

    046513107

     

     

     

    CUSIP No. 046513107 13G Page 10 of 13 Pages

     

    Item 3. If this statement is filed pursuant to §§ 240.13d-1(b), or 240.13d-2(b) or (c), check whether the person filing is a:
       
      (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) ¨ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
      (f) ¨ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
      (g) ¨ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
      (h) ¨ A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
      (i) ¨ A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
      (j) ¨ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with § 240.13d-1(b)(1)(ii)(K).
             
      If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution: ____________.
             
    Item 4. Ownership:
             
      A. Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC
             
        (a) Each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may be deemed to beneficially own 6,512,063 Shares.
             
        (b) The number of Shares that each of Citadel Advisors LLC, Citadel Advisors Holdings LP and Citadel GP LLC may be deemed to beneficially own constitutes 6.4% of the Shares outstanding.
             
        (c) Number of Shares as to which such person has:
             
          (i) sole power to vote or to direct the vote:  0
             
          (ii) shared power to vote or to direct the vote:  6,512,063
             
          (iii) sole power to dispose or to direct the disposition of:  0
             
          (iv) shared power to dispose or to direct the disposition of:  6,512,063

     

     

     

     

    CUSIP No. 046513107 13G Page 11 of 13 Pages

     

      B. Citadel Securities LLC
             
        (a) Citadel Securities LLC may be deemed to beneficially own 21,056 Shares.
           
        (b) The number of Shares that Citadel Securities LLC may be deemed to beneficially own constitutes 0.0% of the Shares outstanding.
           
        (c) Number of Shares as to which such person has:
           
          (i) sole power to vote or to direct the vote:  0
             
          (ii) shared power to vote or to direct the vote:  21,056
             
          (iii) sole power to dispose or to direct the disposition of:  0
             
          (iv) shared power to dispose or to direct the disposition of:  21,056
             
      C. Citadel Securities Group LP and Citadel Securities GP LLC
             
        (a) Each of Citadel Securities Group LP and Citadel Securities GP LLC may be deemed to beneficially own 21,056 Shares.
           
        (b) The number of Shares that each of Citadel Securities Group LP and Citadel Securities GP LLC may be deemed to beneficially own constitutes 0.0% of the Shares outstanding.
           
        (c) Number of Shares as to which such person has:
           
          (i) sole power to vote or to direct the vote:  0
             
          (ii) shared power to vote or to direct the vote:  21,056
             
          (iii) sole power to dispose or to direct the disposition of:  0
             
          (iv) shared power to dispose or to direct the disposition of:  21,056
             

     

     

     

    CUSIP No. 046513107 13G Page 12 of 13 Pages

     

      D. Kenneth Griffin
             
        (a) Mr. Griffin may be deemed to beneficially own 6,533,119 Shares.
           
        (b) The number of Shares that Mr. Griffin may be deemed to beneficially own constitutes 6.4% of the Shares outstanding.
           
        (c) Number of Shares as to which such person has:
           
          (i) sole power to vote or to direct the vote:  0
             
          (ii) shared power to vote or to direct the vote:  6,533,119
             
          (iii) sole power to dispose or to direct the disposition of:  0
             
          (iv) shared power to dispose or to direct the disposition of:  6,533,119

     

    Item 5. Ownership of Five Percent or Less of a Class:
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following. o
       
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person:
       
      Not Applicable
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company:
       
      Not Applicable
       
    Item 8. Identification and Classification of Members of the Group:
       
      Not Applicable
       
    Item 9. Notice of Dissolution of Group:
       
      Not Applicable
       
    Item 10. Certifications:
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

    CUSIP No. 046513107 13G Page 13 of 13 Pages

     

    SIGNATURE

     

    After reasonable inquiry and to the best of its knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

     

    Dated March 18, 2024.

     

    CITADEL SECURITIES LLC   CITADEL ADVISORS LLC
             
    By: /s/ Guy Miller   By: /s/ Seth Levy
      Guy Miller, Authorized Signatory     Seth Levy, Authorized Signatory
             
             
    CITADEL SECURITIES GROUP LP   CITADEL ADVISORS HOLDINGS LP
             
    By: /s/ Guy Miller   By: /s/ Seth Levy
      Guy Miller, Authorized Signatory     Seth Levy, Authorized Signatory
             
             
    CITADEL SECURITIES GP LLC   CITADEL GP LLC
             
    By: /s/ Guy Miller   By: /s/ Seth Levy
      Guy Miller, Authorized Signatory     Seth Levy, Authorized Signatory
             
             
          KENNETH GRIFFIN
             
          By: /s/ Seth Levy
            Seth Levy, attorney-in-fact*

     

     

    *Seth Levy is signing on behalf of Kenneth Griffin as attorney-in-fact pursuant to a power of attorney previously filed with the Securities and Exchange Commission, and hereby incorporated by reference herein. The power of attorney was filed as an attachment to a filing by Citadel Advisors LLC on Schedule 13G for Allakos Inc. on October 13, 2023.

     

     

    Get the next $ATRA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ATRA

    DatePrice TargetRatingAnalyst
    11/9/2023Outperform → In-line
    Evercore ISI
    11/9/2023Buy → Neutral
    H.C. Wainwright
    11/9/2023$31.00 → $1.00Buy → Neutral
    Mizuho
    7/20/2022$8.00 → $3.00Neutral → Sell
    Citigroup
    7/13/2022$10.00Overweight → Neutral
    JP Morgan
    7/13/2022$16.00 → $5.00Buy → Hold
    Stifel
    5/10/2022$15.00 → $8.00Buy → Neutral
    Citigroup
    1/3/2022$26.00 → $27.00Overweight
    JP Morgan
    More analyst ratings

    $ATRA
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13D/A filed by Atara Biotherapeutics Inc.

      SCHEDULE 13D/A - Atara Biotherapeutics, Inc. (0001604464) (Subject)

      5/16/25 6:28:02 PM ET
      $ATRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 8-K filed by Atara Biotherapeutics Inc.

      8-K - Atara Biotherapeutics, Inc. (0001604464) (Filer)

      5/16/25 5:26:51 PM ET
      $ATRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Atara Biotherapeutics Inc.

      SCHEDULE 13G/A - Atara Biotherapeutics, Inc. (0001604464) (Subject)

      5/15/25 9:00:22 PM ET
      $ATRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ATRA
    Financials

    Live finance-specific insights

    See more
    • Atara Biotherapeutics to Announce Third Quarter 2024 Financial Results on Tuesday, November 12, 2024

      Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release third quarter 2024 financial results after market close on Tuesday, Nov 12, 2024. About Atara Biotherapeutics, Inc. Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory. With cutting-edge science and differentiated approach, Atara is the first company in the w

      11/5/24 4:01:00 PM ET
      $ATRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Atara Biotherapeutics Announces Expanded Global Tab-cel® Partnership with Pierre Fabre Laboratories and Third Quarter 2023 Financial Results

      Pierre Fabre Laboratories to License Commercialization Rights to Tab-cel®, including Regulatory, Manufacturing and Development Activities, in the United States and All Remaining Markets Atara to Receive Additional Payments of up to USD 640 Million, Significant Double-digit Tiered Royalties as a Percentage of Net Sales, and Funding of Tab-cel Global Development Costs Tab-cel Global Partnership and Associated Strategic Restructuring Extends Atara Cash Runway into Q3 2025 ATA188 Phase 2 EMBOLD Study Primary Analysis and Communication on Track for Early November Atara to Host Conference Call and Webcast today at 6:00 a.m. PDT / 9:00 a.m. EDT Atara Biotherapeutics, Inc. (NASDAQ:ATRA),

      11/1/23 8:30:00 AM ET
      $ATRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Atara Biotherapeutics to Announce Second Quarter 2023 Financial Results on Tuesday, August 8, 2023

      Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the Company will release second quarter 2023 financial results after market close on Tuesday, August 8, 2023. About Atara Biotherapeutics, Inc. Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions, including multiple sclerosis, that can be rapidly delivered to patients within days. With cutting-edge science and differentiated approach, At

      8/1/23 4:01:00 PM ET
      $ATRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ATRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Atara Biotherapeutics downgraded by Evercore ISI

      Evercore ISI downgraded Atara Biotherapeutics from Outperform to In-line

      11/9/23 9:00:28 AM ET
      $ATRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Atara Biotherapeutics downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Atara Biotherapeutics from Buy to Neutral

      11/9/23 7:32:43 AM ET
      $ATRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Atara Biotherapeutics downgraded by Mizuho with a new price target

      Mizuho downgraded Atara Biotherapeutics from Buy to Neutral and set a new price target of $1.00 from $31.00 previously

      11/9/23 6:45:52 AM ET
      $ATRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ATRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Adiumentum Capital Fund I Lp was granted 75,572 shares (SEC Form 4)

      4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)

      5/16/25 6:26:21 PM ET
      $ATRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • New insider Grant-Huerta Yanina claimed ownership of 39,285 shares (SEC Form 3)

      3 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)

      4/10/25 7:14:26 PM ET
      $ATRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Former EVP, CFO & COO Hyllengren Eric J

      4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)

      4/2/25 7:54:05 PM ET
      $ATRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ATRA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors

      Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, announced the appointment of James Huang and Nachi Subramanian to its Board of Directors, effective following the completion the Company's previously announced $16 million offering that was announced on May 15, 2025. The offering closed on May 16, 2025. Mr. Huang has over 37 years of biotech experience and is the Founder and Managing Partner of Panacea Venture. Prior to Panacea Venture, Mr. Huang was a Managing Partner at Kleiner Perkins (KPCB) China where h

      5/16/25 8:50:00 PM ET
      $ATRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Atara Biotherapeutics Announces First Quarter Financial Results and Operational Progress

      Atara has transferred all manufacturing responsibility to Pierre Fabre Laboratories, including all costs associated with the manufacturing and supply of tabelecleucel for development and commercialization worldwide Atara expects to reduce its operating expenses year-over-year by approximately 65% in 2025 as a result of implemented cost reduction initiatives Atara has entered into an underwriting agreement for an offering with expected gross proceeds of $16 million that Atara believes is sufficient to fund the ongoing activities required to achieve potential BLA approval Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Ba

      5/15/25 8:35:00 AM ET
      $ATRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Atara Biotherapeutics Announces Pricing of $16 Million Offering

      Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the pricing of an offering of 834,237 shares of its common stock at an offering price of $6.61 per share and pre-funded warrants to purchase 1,587,108 shares of its common stock at an offering price of $6.6099 per pre-funded warrant share in an underwritten registered direct offering to a limited number of existing institutional investors, including entities affiliated with Adiumentum Capital Management, EcoR1 Capital, Panacea Venture and Redm

      5/15/25 8:30:00 AM ET
      $ATRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ATRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Gallagher Carol Giltner bought $68,214 worth of shares (270,000 units at $0.25), increasing direct ownership by 143% to 459,418 units (SEC Form 4)

      4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)

      11/15/23 5:07:08 PM ET
      $ATRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Dobmeier Eric bought $101,340 worth of shares (446,825 units at $0.23), increasing direct ownership by 384% to 563,325 units (SEC Form 4)

      4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)

      11/14/23 6:27:14 PM ET
      $ATRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Heiden William K bought $25,330 worth of shares (100,000 units at $0.25), increasing direct ownership by 92% to 209,000 units (SEC Form 4)

      4 - Atara Biotherapeutics, Inc. (0001604464) (Issuer)

      11/14/23 6:29:04 PM ET
      $ATRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $ATRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $ATRA
    Leadership Updates

    Live Leadership Updates

    See more
    • Amendment: SEC Form SC 13G/A filed by Atara Biotherapeutics Inc.

      SC 13G/A - Atara Biotherapeutics, Inc. (0001604464) (Subject)

      11/14/24 6:10:20 PM ET
      $ATRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Atara Biotherapeutics Inc.

      SC 13G/A - Atara Biotherapeutics, Inc. (0001604464) (Subject)

      11/14/24 4:17:31 PM ET
      $ATRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Atara Biotherapeutics Inc.

      SC 13G/A - Atara Biotherapeutics, Inc. (0001604464) (Subject)

      11/12/24 1:29:52 PM ET
      $ATRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Atara Biotherapeutics Appoints James Huang and Nachi Subramanian to Board of Directors

      Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, announced the appointment of James Huang and Nachi Subramanian to its Board of Directors, effective following the completion the Company's previously announced $16 million offering that was announced on May 15, 2025. The offering closed on May 16, 2025. Mr. Huang has over 37 years of biotech experience and is the Founder and Managing Partner of Panacea Venture. Prior to Panacea Venture, Mr. Huang was a Managing Partner at Kleiner Perkins (KPCB) China where h

      5/16/25 8:50:00 PM ET
      $ATRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Eikon Therapeutics Announces the Appointment of Dr. Roy D. Baynes as Executive Vice President and Chief Medical Officer

      Eikon Therapeutics, Inc., a California-based biotechnology company that applies advanced engineering and high-performance computing to the identification of important new medicines, today announced the appointment of Roy D. Baynes, MB, BCh, MMed, PhD, as Executive Vice President and Chief Medical Officer, effective July 11, 2022. A gifted physician-scientist and leading oncologist, Dr. Baynes is among the most experienced – and most successful – clinical development leaders in the biopharmaceutical industry. Dr. Baynes will serve as a consultant to Eikon Therapeutics beginning April 1, 2022 before transitioning to his full-time role as Executive Vice President and Chief Medical Officer in J

      3/23/22 7:30:00 AM ET
      $ATRA
      $NTRA
      $TVTX
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Medical Specialities
      Biotechnology: Pharmaceutical Preparations
    • Atara Biotherapeutics Appoints Cell Therapy and Oncology Commercialization Veteran Ameet Mallik to the Board of Directors

      Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a pioneer in T-cell immunotherapy leveraging its novel allogeneic EBV T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the appointment of Ameet Mallik to the Board of Directors. Mr. Mallik is a biotechnology and pharmaceutical industry expert with a successful track record of bringing innovative oncology therapeutics, including CAR T cell therapy, to market in the U.S. and other countries. With more than 25 years of experience, Mr. Mallik adds relevant and directly applicable management and operational experience that will be instrumental as Atara progresses toward commercial laun

      8/9/21 4:01:00 PM ET
      $ATRA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care